GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £23.55. The ...
A small team of Australian scientists won a rare drug approval – and upended the pharma system
Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...
American Association of Individual Investors4h
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...
Macau Business6h
GSK sees annual profit slide on Zantac drug fallout
British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.
GSK lifts long-term sales outlook on strong Specialty Medicines growth
GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views — Update
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook — 2nd Update
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.
Le Lézard4h
Vaxxas Appoints Leading Global Vaccine Experts as the Company Advances its Needle-Free Vaccination Technology Towards Late-Stage Clinical Trials
Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...
FiercePharma4h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...